期刊文献+

阿托伐他汀对老年大鼠多器官内皮型一氧化氮合酶的影响及其在心肌缺血再灌注中的作用 被引量:8

Effect of atorvastatin on eNOS synthesis in organs of aging rats with myocardial ischemia-reperfusion
暂未订购
导出
摘要 目的观察阿托伐他汀对多器官内皮型一氧化氮合酶(eNOS)合成及eNOS mRNA表达的影响,探讨阿托伐他汀在心肌缺血再灌注过程中对多器官保护作用的可能机制。方法 20月龄Wistar大鼠应用阿托伐他汀灌胃至24月龄,采用结扎冠状动脉方法建立心肌缺血再灌注模型,并设立未用药未手术组、未用药手术组、用药未手术组及用药手术组。应用Western blot方法检测eNOS在各组大鼠心、肝、肾组织的含量,应用RT-PCR方法检测eNOS mRNA的表达情况。同批次同处理24月龄大鼠,分为大剂量他汀组、小剂量他汀组并老年对照组。采用同上方法检测eNOS在各组大鼠心、肝、肾组织的含量,应用Western blot方法检测eNOS在各组大鼠心、肝、肾组织的含量,应用RT-PCR方法检测eNOS mRNA的表达情况。结果阿托伐他汀能显著提高老年大鼠心、肝、肾器官内eNOS合成(P<0.05)及eNOS mRNA的表达(P<0.05),且与心肌缺血再灌注无关。引入药物剂量分组后,与老年对照组相比,他汀组eNOS合成及eNOS mRNA的表达显著增加(P<0.05);其中,大剂量他汀组较小剂量他汀组增加更为显著(P<0.05)。结论阿托伐他汀可使老年大鼠多器官内eNOS合成及eNOS mRNA的表达增加,部分解释了阿托伐他汀在心肌缺血再灌注过程中对多器官功能的保护作用。 Objective To observe the effect of atorvastatin on eNOS synthesis in the vital organs of aging rats and explore its mechanism for protection against myocardial ischemia-reperfusion injury. Methods Twenty-month-old Wistar rats were given daily atorvastatin lavage for 4 months. Myocardial ischemia-reperfusion model was established by ligating the coronary artery. The rats were randomized into normal control group, untreated model group, medication without surgery group, and atorvastatin-treated surgical group. The content of eNOS in the heart, liver and kidneys was detected by Western bloting, and eNOS mRNA expression by RT-PCR. The effects of different doses of atorvastatin on eNOS expressions were also evaluated. Results Atorvastatin significantly promoted eNOS synthesis in the heart, liver and kidney of the rats (P〈0.05) regardless of myocardial ischemia-reperfusion. A higher dose of atorvastatin caused a more obvious increase of eNOS protein and mRNA expression in the vital organs of the aging rats (P〈0.05). Conclusion Atorvastatin can increase eNOS synthesis in the vital organs of aging rats, which partially explains the organ-protective effect of atorvastatin against myocardial ischemia- reperfusion.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2012年第12期1708-1712,共5页 Journal of Southern Medical University
基金 国家自然科学基金(30872713)~~
关键词 老年 阿托伐他汀 缺血再灌注 内皮型一氧化氮合酶 aging atorvastatin ischemia and reperfusion endothelial nitric oxide synthase
  • 相关文献

参考文献17

  • 1Laufs U, La FV, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors[J]. Circulation. I998, 97(12): 1129-35.
  • 2Liao JK, Bettmann MA, Sandor T, et al. Differential impairment ofvasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis [J]. Circ Res, 1991, 68(4): 1027-34.
  • 3张今尧,王浩,叶平.阿托伐他汀对老年大鼠心肌缺血再灌注损伤及多器官功能的保护作用[J].南方医科大学学报,2012,32(3):322-328. 被引量:11
  • 4Janssens S, Flaherty D, Nong Z, et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats[J]. Circulation, 1998, 97(13): 1274-81.
  • 5Umar S, van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart[J]. Mol Cell Biochem, 2010, 333: 191-201.
  • 6Vanhoutte PM. Endothelial dysfunction and atherosclerosis[J]. Eur Heart J, 1997, 18(Suppl E): E19-29.
  • 7Laufs U, Gertz K, Dimagl U, et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, up-regulates endothelial nitric oxide synthase and protects from ischemic stroke in mice[J]. Brain Res, 2002, 942 (1/2): 23-30.
  • 8Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase[J]. J Biol Chem, 1998, 273(37): 24266-71.
  • 9Plenz GA, Hofnagel O, Robenek H. Differential modulation of caveolin-1 expression in cells of the vasculature by statins[J]. Circulation, 2004, 109(2): e7-8.
  • 10Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotesangiogenesis in normocholesterolemic animals[J]. Nat Med, 2000, 6 (9): 1004-10.

二级参考文献31

  • 1孟红,张英杰.阿托伐他汀对大鼠缺血再灌注心肌细胞凋亡的影响[J].中国全科医学,2009,12(6):465-468. 被引量:15
  • 2万大国,孙利强,吴帆,刘宗芳,曾秋棠.阿托伐他汀对大鼠急性心肌梗死后心肌细胞凋亡的影响[J].山东医药,2006,46(29):26-27. 被引量:2
  • 3Arca M.Atorvastatin:a safety and tolerability profile[J].Drugs,2007,67(Suppl 1):63-9.
  • 4Law M,Rudnicka AR.Statin safety:a systematic review[J].Am JCardiol,2006,97:52C-60C.
  • 5Escobar C,Echarri R,Barrios V.Relative safety profiles of highdose statin regimen[s J].Vasc Health Risk Manag,2008,4:525-33.
  • 6Moreno M,Ramalho LN,Sancho-Bru P,et al.Atorvastatinattenuates angiotensin II-induced inflammatory actions in the liver[J].Am J Physiol Gastrointest Liver Physiol,2009,296:G147-56.
  • 7Tokunaga T,Ikegami T,Yoshizumi T,et al.Beneficial effects offluvastatin on liver microcirculation and regeneration after massivehepatectomy in rat[s J].Dig Dis Sci,2008,53:2989-94.
  • 8Schwartz Y,Dushkin MI,Komarova NI,et al.Cholesterol-inducedstimulation of postinflammatory liver fibrosis[J].Bull Exp BiolMed,2008,145:692-5.
  • 9Dold S,Laschke MW,Lavasani S,et al.Simvastatin protects againstcholestasis-induced liver injury[J].Br J Pharmacol,2009,156:466-74.
  • 10Fitzgerald JP,Chou SY,Franco I,et al.Atorvastatin amelioratestubulointerstitial fibrosis and protects renal function in chronicpartial ureteral obstruction case[s J].J Urol,2009,182:1860-8.

共引文献10

同被引文献102

引证文献8

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部